199 related articles for article (PubMed ID: 22093486)
1. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis.
Korets R; Seager CM; Pitman MS; Hruby GW; Benson MC; McKiernan JM
BJU Int; 2012 Jul; 110(2):211-6. PubMed ID: 22093486
[TBL] [Abstract][Full Text] [Related]
2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
3. Delay of surgery in men with low risk prostate cancer.
O'Brien D; Loeb S; Carvalhal GF; McGuire BB; Kan D; Hofer MD; Casey JT; Helfand BT; Catalona WJ
J Urol; 2011 Jun; 185(6):2143-7. PubMed ID: 21496847
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
5. Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?
Graefen M; Walz J; Chun KH; Schlomm T; Haese A; Huland H
Eur Urol; 2005 Jun; 47(6):756-60. PubMed ID: 15925069
[TBL] [Abstract][Full Text] [Related]
6. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
7. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
[TBL] [Abstract][Full Text] [Related]
8. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
[TBL] [Abstract][Full Text] [Related]
9. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
10. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
[TBL] [Abstract][Full Text] [Related]
11. Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men?
Lee SE; Lee WK; Jeong MS; Abdullajanov M; Kim DS; Park HZ; Jeong SJ; Yoon CY; Byun SS; Choe G; Hong SK
BJU Int; 2011 Apr; 107(8):1250-5. PubMed ID: 20880194
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
13. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.
Servoll E; Saeter T; Vlatkovic L; Lund T; Nesland J; Waaler G; Axcrona K; Beisland HO
BJU Int; 2012 May; 109(10):1489-94. PubMed ID: 21933333
[TBL] [Abstract][Full Text] [Related]
14. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
15. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
[TBL] [Abstract][Full Text] [Related]
16. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
17. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
[TBL] [Abstract][Full Text] [Related]
18. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Presti JC; Terris MK;
J Urol; 2006 Apr; 175(4):1298-302; discussion 1302-3. PubMed ID: 16515984
[TBL] [Abstract][Full Text] [Related]
19. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
20. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
